London, 22 July 2015: Technavio, the independent tech-focused global research firm, has published a report on the PTCA balloon catheter market in China 2015-2019, which is to grow rapidly during the forecast period of 2014-2019 at a CAGR of 14.75%.
The high incidence of CVDs and CHDs, advances in technology, and the increased number of elderly, diabetic, and obese individuals are propelling market growth. Changing lifestyles, high demand for minimally invasive procedures, and the expected launch of pipeline PTCA balloon catheters will also contribute to market growth.
“Advances in PTCA balloon catheters have led to an increased number of clinical trials and the launch of new products in the market,” says Faisal Ghaus, Vice President of Technavio.
“These procedures are performed through small incisions in the body and can be used to treat plaque obstructions in the arteries of the heart and other blood vessels of peripheral organs, such as the brain and kidneys.”
Key Market Drivers
- Growing Geriatric Population
- High Expenditure on Healthcare
- Rise in Incidence of CVDs
- Increased Number of Specialized Cardiologists
Key Market Trends
- High Demand for Minimally Invasive Procedures
- Government Support for Local Manufacturers
- Growing Popularity of Hybrid Procedures
Key Market Vendors
- Abbott Laboratories
- Boston Scientific Corp.
- Medtronic plc
- MicroPort Scientific Corp.
- Terumo Corp
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
